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Abstract
Background: Molecular biomarkers that are based on mRNA transcripts are being developed for the diagnosis and
treatment of a number of diseases. DNA microarrays are one of the primary technologies being used to develop
classifiers from gene expression data for clinically relevant outcomes. Microarray assays are highly multiplexed
measures of comparative gene expression but have a limited dynamic range of measurement and show
compression in fold change detection. To increase the clinical utility of microarrays, assay controls are needed that
benchmark performance using metrics that are relevant to the analysis of genomic data generated with biological
samples.
Results: Ratiometric controls were prepared from commercial sources of high quality RNA from human tissues
with distinctly different expression profiles and mixed in defined ratios. The samples were processed using six
different target labeling protocols and replicate datasets were generated on high density gene expression
microarrays. The area under the curve from receiver operating characteristic plots was calculated to measure
diagnostic performance. The reliable region of the dynamic range was derived from log2 ratio deviation plots
made for each dataset. Small but statistically significant differences in diagnostic performance were observed
between standardized assays available from the array manufacturer and alternative methods for target generation.
Assay performance using the reliable range of comparative measurement as a metric was improved by adjusting
sample hybridization conditions for one commercial kit.
Conclusions: Process improvement in microarray assay performance was demonstrated using samples prepared
from commercially available materials and two metrics - diagnostic performance and the reliable range of
measurement. These methods have advantages over approaches that use a limited set of external controls or
correlations to reference sets, because they provide benchmark values that can be used by clinical laboratories to
help optimize protocol conditions and laboratory proficiency with microarray assays.
Background
As one of the first ‘omic scale technologies in wide-
spread use, microarrays provide a test case for addres-
sing issues associated with highly multiplexed assays and
high dimensional datasets. During the last decade, com-
munity-wide efforts were initiated to address concerns
that arose with the increased use of microarray
technology in research. These concerns include data
comparability, the lack of universal controls for gene
expression experiments, the need for data reporting
standards, and methods for determining appropriate sta-
tistical approaches. The MicroArray Quality Control
(MAQC) projects led by the FDA [1,2], the External
RNA Controls Consortium under the leadership of the
National Institute of Standards and Technology [3], and
the Microarray Gene Expression Database (MGED)
group which developed the MIAME (Minimum Infor-
mation About a Microarray Experiment) standards [4]
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microarray measurements, an essential step for the use
of this technology in biomedical applications.
The use of microarray-based clinical tests, although
currently limited, is expected to expand with the
increasing incorporation of personalized medicine into
medical practice. The availability of clinically directed
standards would help promote the development of
highly multiplexed gene expression assays in laboratory
medicine [5]. The use of microarrays in clinical diagnos-
tics will require assurance that clinical laboratories are
and remain proficient in using this technology. Microar-
rays are designed for high throughput assessment of
relative mRNA levels, but comparative expression mea-
surements are constrained by limits in the dynamic
range of detection [6]. Expression ratios derived from
microarray data are compressed in comparison to quan-
titative real time polymerase chain reaction (qRT-PCR)
assay data, especially for probes with high signal intensi-
ties [7]. The dynamic range and reliability of measure-
ments on microarray assays can be further
compromised by suboptimal laboratory proficiency with
this technology. Routine performance assessments using
reference samples are highly recommended as a best
practice for the generation of high quality microarray
data [8]. External RNA controls provided by array man-
ufacturers have utility for evaluating the success or fail-
ure of certain sample processing steps but are limited in
number and, because they do not span the range of
intensities in biological samples, are not representative
of all genes on a microarray [9]. The biologically com-
plex samples used in the MAQC-I project to assess
microarray data comparability across platforms have
been widely used but, unlike samples in a typical analy-
sis, are not closely related. MAQC-I sample A is a uni-
versal human reference RNA (UHRR) prepared by
pooling RNA from multiple cell lines [10] and MAQC-I
sample B consists of human brain reference RNA
(HBRR) prepared from multiple individuals [1]. The dif-
ference in mRNA content between MAQC-1 samples A
and B hinders the use of MAQC sample titrations to
measure the ability to detect known changes between
samples [11]. Typically, the MAQC samples have been
used for performance comparisons by correlation of
results to the reference microarray datasets or to the
qRT-PCR data generated for a subset of analytes in the
MAQC samples on the TaqMan platform (for examples,
see [12,13]). Correlations to historical reference sets
measure the degree of similarity to benchmark data but
not necessarily an improvement in performance over
reference set levels.
Objective criteria to measure performance on microar-
rays can be developed for samples which are designed to
have known differences in expression. We developed a
system for assessing technical performance with micro-
array assays that involves two biologically complex sam-
ples (mixed tissue ratiometric controls (MTRC)) that are
representative of experimental samples [14]. MTRC are
two samples with three or four RNA components mixed
in different proportions. Technical performance is based
on quantifiable measures of diagnostic accuracy and the
reliable region of measurement. Diagnostic accuracy is
the ability of a microarray assay to correctly detect true
positive and negative changes in the MTRC samples
based on differences in tissue-selective transcripts that
are consistent with the ratios of mixed tissue RNA. The
area under the curve (AUC) from receiver operating
characteristic (ROC) plots summarizes the technical per-
formance in a single benchmark value based on mea-
surements of over 100 true positive and negative
analytes in the MTRC. The utility of this approach has
been evaluated using rat whole genome microarrays
with mixtures of total RNA from four rat tissues (liver,
brain, testis, and kidney) known to have distinctly differ-
ent expression patterns [14,15]. Translating this
approach for laboratories that analyze clinical samples is
challenged by quality issues with human tissue RNA. In
this manuscript, we descri b eam e t h o df o rt h ed e s i g n
and use of performance standards for human gene
expression arrays that use commercially available RNA
and include metrics that identify the most reliable
region of the dynamic range of measurement.
Results
Selection of components for the human MTRC
Mixed tissue ratiometric controls for monitoring perfor-
mance with microarrays are two samples that are com-
posed of RNA of high and reproducible quality from 3
or 4 different tissues that are sufficiently different in
gene expression. The samples are designated MTRC-3
or MTRC-4 if they are composed of three or four differ-
ent RNA sources, respectively. The four components of
the human MTRC-4 used as the example in this study
are UHRR, HBRR, liver RNA, and skeletal muscle RNA.
Two components of the MTRC-4 (UHRR and HBRR)
were chosen because they have been extensively tested
in the MAQC-I project and are commercially available
in large lots. The additional components of the MTRC-
4 were chosen from the normal human tissues that had
high levels of selective gene expression in published
reports. Son et al. identified testis, liver, brain (cerebel-
lum and cerebrum), skeletal muscle, and heart as the
tissues with the highest number of organ-specific genes
using a set of cDNA microarray data from 19 different
organs from 30 individual donors [16]. Of the 46 human
tissue samples and cell lines analyzed on Affymetrix
Human Genome U95A arrays by Su et al.,t h el a r g e s t
numbers of specifically expressed gene transcripts were
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gland, kidney, heart, and cerebellum [17]. We surveyed
the quality of commercial sources of RNA for several of
the tissues with high levels of selective expression (see
Table 1). Of the six tissue sources tested in addition to
HBRR and UHRR, RNA from human liver and skeletal
muscle had the highest level of sample integrity across
multiple lots. All of the lots of human liver and skeletal
muscle RNA surveyed had RNA Integrity Number (RIN)
values higher than or equal to 8, which is the threshold
level of RNA quality that had no effect on the detection
of known changes in gene expression on Affymetrix
expression arrays [18].
Selection of analytes for the human MTRC-4
Performance assessments made using the MTRC are
based on tissue-selective analytes. For MTRC analyte
selection, tissue-selectivity was defined as an average sig-
nal intensity that is ten-fold higher in one tissue than
the other tissues in the MTRC. For the MTRC-4,
UHRR, HBRR, liver RNA, and skeletal muscle RNA
were individually labeled and hybridized to Affymetrix
Human Genome U133A 2.0 arrays on separate dates to
create three replicate datasets. For each probe set in
each tissue, the difference between its log2 signal inten-
sity in that tissue and its maximum value in the remain-
ing tissues was calculated to determine a tissue-selective
index (TSI) for each dataset. Using a mean TSI cutoff of
3.22 log2 units, a total of 1035 tissue-selective analytes
were identified for the MTRC-4 that included 429
HBRR-, 255 liver RNA-, 197 UHRR-, and 154 skeletal
muscle RNA-selective probe sets (see Additional file 1 -
Lists of MTRC-4 analytes for Affymetrix HG-U133A 2.0
arrays).
Evaluation of components for the human MTRC-4
UHRR, liver RNA, HBRR, and skeletal muscle RNA
were mixed together in two samples to yield ratios of
1:1, 1.5:1, 2:1, and 1:4, respectively, between Mix1 and
Mix2 in the MTRC-4 tested in this study. Commercial
sources of human liver and skeletal muscle RNA were
available in lots prepared from single individuals in lim-
ited amounts. To assess the impact of the use of differ-
ent lots of RNA on the reproducibility of results with
the MTRC-4, we compared 6 single assays of the
MTRC-4 that all used Method 2A for target preparation
but different lots of liver RNA and of skeletal muscle
RNA (Batches 1-4 in Table 1). An AUC was derived for
Table 1 Source and quality of human tissue RNA used in testing
MTRC Batch
Tissue Provider Catalogue No. Lot No. RIN Analyte
Selection
12345
120000320 9.4 X
Liver Ambion AM7960 40000129 9.1 X X
811001 8.2 X X
905002 8.1 X
CHTN
a NA NA 8.7 X
811001 8.5 X X X
Ambion (AM7982) 2060298 8.3 X
906002 8 X X
HBRR Ambion AM6050 105055201A 7.6 X X X X X X
UHRR Stratagene 740000 1130623 8.2 X X X X X
580049 8.2
Lung Stratagene 540019 6051745 8.2
6037468 6.2
Kidney Ambion AM7976 70100119 7.8
Testes Ambion AM7972 5060396 7
Placenta Ambion AM7950 202009 6.7
aCooperative Human Tissue Network
Pine et al. BMC Biotechnology 2011, 11:38
http://www.biomedcentral.com/1472-6750/11/38
Page 3 of 11each singlicate assay using the log2 ratio method [14]
and used for the comparisons. There was a statistically
significant difference in AUC using the MTRC-4 made
with skeletal muscle RNA prepared from donor tissue
(Trial 1) compared to the MTRC-4 made with commer-
cial sources of skeletal muscle RNA (Table 2). The
AUCs for 1.5-fold and 2-fold change detections were
statistically different between Trial 1 using MTRC-4
Batch 1 and the five datasets that used MTRC-4 Batches
2-4. The 4-fold AUC was significantly different between
Trial 1 and two of the replicate datasets of MTRC-4
Batch 4 (P < 0.05). Batches 2, 3 and 4 all used commer-
cial sources of RNA. Different lots of liver and skeletal
muscle RNA were used in Batch 2 than in Batches 3
and 4. Batches 3 and 4 share the same lot of skeletal
muscle RNA but contain different lots of liver RNA (see
Table 1). No difference in 2-fold or 4-fold AUC was
observed between Batches 2, 3, and 4. The 1.5-fold
AUC was significantly different between Trial 2 using
Batch 2 RNA and datasets using Batch 3 or 4 RNA (P <
0.05). These results indicate that the human MTRC-4
could be generated using different commercial lots of
good quality human RNA with minor differences in per-
formance. Although these differences were less than
those observed between technical replicates with some
of the methods used in this study (data not shown), the
same batch of MTRC should be used for systematic
assessments of the effect of specific variables on labora-
tory performance.
Evaluation of diagnostic performance
To demonstrate the utility of the human MTRC for
assessing small improvements in performance, we evalu-
ated the impact of differences in labeling protocols and
kits on benchmark values. Target labeling methods are a
recognized source of variation in microarray data
[19,20]. Minor differences in target labeling methods
can introduce systematic bias in signal intensity, due to
differences in target sequence or length, which may
impact the statistical detection of differential gene
expression. For this study, Batch 4 of the MTRC-4 was
labeled using different commercially available kits with
several variations in laboratory protocol that were within
the manufacturers’ recommendations for length of time
of labeling reaction, amount of total RNA input, and
amount of target hybridized to arrays (see Table 3). The
studies included two generations of the array manufac-
turer’s labeling kit (Affymetrix IVT and IVT Express)
that use the Eberwine method to generate linear ampli-
fied RNA (aRNA) targets and one kit that generates a
single stranded (ss)-cDNA target through isothermal lin-
ear amplification of cDNA (Nugen Ovation V2) [21].
For each labeling method, a p-value was calculated for
each MTRC-4 analyte using a paired t-test comparison
of normalized log2 signals from array data for three
replicate assays of Mix1 and Mix2. A ROC-plot was
generated for each of the true positive subsets in the
MTRC-4 datasets (for 1.5-, 2-, and 4-fold changes) com-
pared to the true negative (1-to-1) subset and the corre-
sponding AUCs calculated as described previously [14].
No significant difference in the accurate detection of
changes of two-fold or greater was observed between
labeling methods (Table 3). However, there was a statis-
tically significant difference in 1.5-fold AUC between
datasets generated with aRNA targets and datasets gen-
erated with ss-cDNA targets (P < 0.01). Of the ratios in
the MTRC-4, 1.5-fold changes are more sensitive to
noise [14] which can be contributed by factors such as
variation between replicates. A lower degree of reprodu-
cibility between analyte ratios for technical replicates
was observed for data generated using Method 3 com-
pared to Method 1, which may be due in part to the
greater familiarity of our laboratory with Methods 1 and
2. A Spearman’s rank correlation coefficient (r) between
each possible comparison of technical replicates was cal-
culated using the log2 ratios of 1035 tissue-selective ana-
lytes. The mean r (± standard deviation) for datasets
1A-4, 1B-4, 3A-4, and 3B-4 was 0.897 ± 0.02, 0.928 ±
0.004, 0.861 ± 0.019, and 0.852 ± 0.003, respectively. No
significant difference in 1.5-fold AUC was found
between two versions of a manufacturer’s kit (datasets
1A-4 and 2A-4) or between variations in the aRNA pro-
tocol in the time of labeling (datasets 1A-4 and 1B-4).
There was also no significant difference in the AUCs
when the amount of ss-cDNA hybridized to arrays was
changed within a protocol (dataset 3A-4 vs. 3B-4).
Determination of reliable range of measurement
Comparative expression data from microarrays is con-
strained at the upper and lower regions of signal inten-
sity by the output range of the scanner and the noise
inherent in measuring low intensity signals, respectively
[6]. A Ratio-Intensity plot (RI-plot) of MTRC data pro-
vides a visualization of the intensity-dependent
Table 2 Differences in performance between MTRC-4
batches labeled with the same method
AUC
Dataset Batch 4-fold 2-fold 1.5-fold
Trial 1 1 0.990* 0.991** 0.944**
Trial 2 2 0.999 1.000 0.963*
Trial 3 3 0.995 1.000 0.981
2A-4_rep1 4 1.000 1.000 0.982
2A-4_rep2 4 0.999 1.000 0.983
2A-4_rep3 4 1.000 1.000 0.983
*Statistically different from italicized values in the same column (P < 0.05).
**Statistically different from all other values within the same column (P <
0.05).
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as shown in Figure 1A for dataset 1A-4. The regions at
the upper and lower limits of detection where data con-
v e r g ea n dt h er e g i o nw i t h i nt h ed y n a m i cr a n g et h a t
remains linear can be established with further analysis.
We developed a metric, the reliable range, to quantify
the linear region of the dynamic range of measurement
using the MTRC analytes. This metric can also serve as
a benchmark value for process improvement. A reliable
range of measurement can be calculated by plotting the
log2 ratio deviation (LRD) for MTRC analytes as a
function of signal intensity. The LRD is the difference
between the observed and expected ratio for each
MTRC analyte. In LRD-plots, analytes are rank ordered
by intensity and divided into bins containing approxi-
mately equal numbers of data points. Next, the mean
and standard deviation of the LRD and the mean and
range of intensities are calculated for each bin and
plotted. Finally, the LRD is used in a chi-square test to
evaluate each bin as follows:
χ2
bin =
n 
i=1
(Observed − Expected)
2
s2 =
n 
i=1
LRD2
s2 (1)
where n is the number of analytes per bin. The stan-
dard deviation (s)i nt h el o g 2 ratios of all probe sets is
used as the variance estimate and a comparison to the
c
2 distribution at a = 0.01 is used to evaluate the good-
ness of fit within each bin. The set of contiguous bins
that pass the c
2 test is identified and used to define the
upper and lower limits of a reliable range of measure-
ment using the maximum and minimum intensities
from the “passing” bins, respectively (see Figure 1B). By
binning LRD values by signal intensity, the LRD-plot
demarcates regions of the dynamic range where ratios
significantly deviate from their target values due to
noise or ratio compression.
The reliable range was calculated for each dataset that
was generated using a different labeling method (Figure
2). The shortest reliable range was observed for dataset
3A-4. The LRD-plot for dataset 3A-4 shows that about
40% of the MTRC analytes lay outside the reliable range
(Figure 3A-B). A similar result is seen in Figure 2,
where the interquartile range of the MTRC analytes for
dataset 3A-4 extends beyond the reliable range. An
adjustment in the 3A-4 protocol was made in Method
3B that reduced the amount of target hybridized to
arrays and resulted in a marked increase in length of
the reliable region of measurement (Figures 2 and 4A-
Table 3 Comparison of AUCs derived with the MTRC-4 and MTRC-3 using different labeling protocols
Variations in method AUC
Dataset Method MTRC
design
a
Kit Total RNA
input
(μg)
Labeling
time
(hr)
Target
hybridized
(μg)
b
4-fold 2-fold 1.5-fold
1A-4 1A 4 IVT Express 0.1 16 6.5 0.99 0.99 0.95
1B-4 1B 4 IVT Express 0.1-0.2 4 6.5 0.99 0.98 0.93
2A-4 2A 4 IVT 5 16 6.5 0.98 0.97 0.93
2A-3 2A 3 IVT 5 16 6.5 - - 0.95
3A-4 3A 4 Ovation 0.02 1 2.2 0.99 0.97 0.87*
3B-4 3B 4 Ovation 0.02 1 0.55 0.99 0.98 0.89*
3C-3 3C 3 Ovation 0.1 1 0.55 - - 0.88*
aThe MTRC-4 design was tested with MTRC Batch 4. The MTRC-3 design was tested with MTRC Batch 5.
bThe target is aRNA for Methods 1 and 2 and cDNA for Method 3.
*Statistically different from italicized values (P < 0.01).
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Figure 1 Log2 ratio distribution for MTRC dataset 1A-4.( A )R I -
plot. Each analyte is represented by an open circle that is colored
for tissue selective expression. Red = HBRR-selective (target log2
ratio of 1), green = liver RNA-selective (target log2 ratio of 0.585),
blue = skeletal muscle RNA-selective (target log2 ratio of -2), and
black = UHRR-selective (target log2 ratio of 0). (B) LRD-plot. Each
circle corresponds to the mean LRD for analytes binned by mean
log2 intensity and is colored by statistical test result. Green = passed
c
2 test and red = failed c
2 test. y-error bars = s per bin and x-error
bars = intensity range of bin. White region = reliable range and
dark gray region = outside the dynamic range. Dashed line = s (the
standard deviation of the log2 ratios for all probe sets).
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Page 5 of 11B). About 85% of the MTRC-4 analytes reside within the
reliable range in dataset 3B-4. After protocol optimiza-
tion, the results are in agreement with previous studies
[22] that showed a larger dynamic range of measure-
ment with the linear isothermal amplification methods
compared to T7 RNA polymerase based methods tradi-
tionally used for sample generation on Affymetrix
arrays.
Optional design for the human MTRC
Mixed tissue ratiometric controls can also be designed
that focus on a single target ratio of interest. We exam-
ined the utility of three component MTRC (MTRC-3)
designed to have one component that is 1.5-fold higher
in Mix1 than Mix2, one component that is 1.5-fold
lower in Mix1 than Mix2, and one component at a 1-
to-1 ratio for normalization. To choose which RNA
source in the MTRC-4 to exclude in the MTRC-3, we
systematically omitted one of the four RNAs in the
MTRC-4 and recalculated the number of tissue-selective
analytes amongst the remaining three RNAs in the com-
parison. Excluding skeletal muscle RNA, liver RNA, or
HBRR produced 1085, 952, or 773 analytes, respectively.
The highest number of tissue-selective analytes (1151)
was achieved by leaving out UHRR (see Additional file 2
- Lists of MTRC-3 analytes for Affymetrix HG-U133A
2.0 arrays). These results were expected, since the
UHRR is designed to cover a large portion of the tran-
scriptome [10]. Further evaluation of the use of the
MTRC-3 design in performance assessments was carried
out with mixes that contained human skeletal muscle
RNA, human liver RNA, and HBRR in 1:1.5, 1.5:1, and
1:1 ratios. An example of an RI-plot and an LRD-plot
generated using the MTRC-3 is shown in Figure 5.
Diagnostic performance measured with the 1.5-fold
AUC was similar between MTRC-3 and MTRC-4 data-
sets that were generated using the same labeling meth-
ods. No significant difference was observed between 1.5-
fold AUCs for MTRC-3 dataset 2A-3 and MTRC-4
dataset 2A-4 that were both labeled using Method 2A
or between MTRC-3 dataset 3C-3 and MTRC-4 datasets
3A-4 and 3B-4 that all used variations of Method 3,
despite differences in the identity and number of
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Figure 2 Reliable range and analyte distributions for MTRC-4
and MTRC-3 datasets that used different labeling protocols.
The distribution of MTRC analytes in each dataset is depicted as a
boxplot with the interquartile range represented by a black
rectangle, connected by whiskers to the minimum and maximum
signal for all analytes (solid boxes). Open squares correspond to the
ends of the dynamic range, the minimum and maximum signals for
all probe sets. Gray rectangles represent the reliable range for each
labeling method. The length of the reliable range in log2 units is
indicated on the right y-axis.
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Figure 3 Log2 ratio distribution for MTRC dataset 3A-4.( A )R I -
plot. Same format as for Figure 1. (B) LRD-plot. Same format as for
Figure 1.
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Similar to the MTRC-4, significant differences were
observed between MTRC-3 datasets generated with dif-
ferent types of targets (aRNA vs. ss-cDNA). A statisti-
cally significant difference in diagnostic performance
was observed between dataset 2A-3 that used the
MTRC-3 with a linear isothermal amplification method
and dataset 3C-3 that used the MTRC-3 with the T7
RNA polymerase based amplification method to gener-
ate target for hybridization to arrays (Table 3). A longer
reliable range and dynamic range of measurement seen
for Method 3 compared to Methods 1 and 2 with the
MTRC-4 and in published reports [22] were also
observed with MTRC-3 dataset 3C-3 compared to
MTRC-3 dataset 2A-3 (Figure 5).
Discussion
The use of human MTRC samples which contain known
changes in expression along the dynamic range of mea-
surement with the reliable range metric introduced in
this manuscript provide a mechanism for clinical labora-
tories conducting microarray assays to benchmark per-
formance, assess laboratory proficiency, and measure
process improvement. Process drift or process improve-
ment, introduced through automation of procedures or
changes in reagents, equipment, operator, or platforms,
may involve relatively subtle effects on microarray data.
For example, in this study we evaluated the effect of a
protocol option with a reduced time for target labeling
(Method 1A vs. 1B). Our results indicated that the
shorter incubation time could be used without signifi-
cantly impacting assay performance. For these process
improvement applications, we have found that a test for
accurate measurement of 1.5-fold changes in compara-
tive expression is a better discriminator of subtle effects
on performance than assaysf o rc h a n g e st h a ta r et w o -
fold or higher. A target ratio of 1.5-fold is included in
the MTRC-4 as one of 4 components or in the MTRC-3
as the single true positive change. We recommend using
the 1.5-AUC metric, which incorporates a measure of
diagnostic accuracy and proficiency in replication of
results with the MTRC, as a first tier test for process
improvement.
Although correlation to reference sets or within repli-
cates is often used to assess performance on microar-
rays, this metric is of limited value for measuring
improvement in laboratory techniques. Datasets gener-
ated using methods 3A and 3B had similar mean Pear-
son’s correlation coefficients (data not shown) and
Spearman’s rank correlation coefficients for ratio repro-
ducibility between technical replicates. However, a clear
improvement in the RI-plot (Figures 3A and 4A) and in
t h er e l i a b l er a n g ev a l u e( F i g u r e2 )c o u l db eo b s e r v e d
w i t hac h a n g ei np r o t o c o lt h a tr e d u c e dt h ea m o u n to f
target hybridized to arrays (Method 3B vs. 3A). Optimal
results with microarray assays are best obtained using
measurements that avoid the boundaries of the dynamic
range [6]. The MTRC contain hundreds of analytes with
known target ratios that span the dynamic range of
measurement and that serve as input values into reliable
range estimates. The reliable range of measurement that
is calculated with the MTRC from LRD-plots is a
benchmark value for evaluating an acceptable perfor-
mance level for laboratory protocols.
We demonstrated two options in sample design for
mixed tissue ratiometric controls. The same metrics
(ROC-plot AUCs, reliable range from LRD-plots) can be
calculated with either design and yielded similar results.
The MTRC-3 design is easily tunable to measure a tar-
get ratio of interest and has an advantage over the
MTRC-4 in requiring only 3 different sources of reliably
good quality human tissue RNA. The human MTRC-4
is directly comparable to the previously described rat
MTRRM design used to illustrate the utility of a ROC-
plot AUC to identify outliers in performance in a large
set of proficiency testing data [14,15].
Previously, we have described methodology for using
the MAQC samples A and B, and two dilutions of A
and B, for performance assessments based on ROC-plot
metrics [23]. However, these samples have limitations.
The MAQC samples A-D each contain 1 or 2 tissues
and the observed differences between total RNA compo-
nents do not correspond to mixed ratios without adjust-
ment for the projected difference in mRNA content
between UHRR and HBRR [11]. The MTRC-4 design
tested in this study limits the skewing effect of UHRR
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Figure 5 Log2 ratio distribution for MTRC dataset 2A-3.( A )R I -
plot. Each analyte is represented by an open circle that is colored
for tissue selective expression. Green = liver RNA-selective (target
log2 ratio of 0.585), blue = skeletal muscle RNA-selective (target log2
ratio of -0.585), and red = HBRR-selective (target log2 ratio of 0). (B)
LRD-plot. Same format as for Figure 1.
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PCR data generated for the MAQC-I project can be
used as the basis for selecting limited sets of true posi-
tive and true negative analytes [23]. However, this
approach yields a low number of analytes with limited
statistical power for calculating an AUC from a ROC-
plot or determining the reliable range from an LRD-
plot. The addition of 1 or 2 different human tissue RNA
components to MAQC samples A and/or B creates a
two-sample system that is better suited for monitoring
process improvement with microarray assays. Although
this study is limited to Affymetrix gene expression
arrays, we have previously shown that the MTRC sam-
ples and metrics can be used on other platforms [14,15].
Conclusions
While DNA microarrays are widely used in medical
research in developing improved assays for prediction or
diagnosis of disease or for assessing the efficacy and
adverse effects of pharmaceuticals, their use in clinical
practice is currently limited. One microarray-based tran-
scriptional profiling assay is currently approved by the
FDA for predicting responsiveness to certain therapeutic
interventions for breast cancer and several others are
under development [24]. The expanded use of microar-
ray technology in clinical medicine would be enabled by
the implementation of methods for monitoring and
optimizing laboratory performance. The methods for
measuring performance on human genome-wide micro-
arrays that are described in this manuscript fit this pur-
pose and can be performed by clinical laboratories using
samples prepared from commercially available sources.
Methods
RNA
Human tissue RNA was obtained from Ambion
(Applied Biosystems, Carlsbad, CA) or Stratagene (Agi-
lent Technologies Inc., Santa Clara, CA). The catalog
and lot numbers of the products tested are indicated in
Table 1. RNA was also prepared from human skeletal
muscle tissue using a Qiagen TissueLyser and Qiagen
RNeasy miniprep kits (Qiagen, Valencia, CA). The
donor tissue was obtained from amputation procedures
through the Cooperative Human Tissue Network which
is funded by the National Cancer Institute. The protocol
for this study was reviewed by the FDA Research Invol-
ving Human Subjects Committee.
RNA quantification and assessment of purity was per-
formed on a NanoDrop spectrophotometer (ThermoScien-
tific, Wilmington, DE). RNA quality was assessed using an
Agilent RNA 6000 Nano kit, an Agilent Bioanalyzer (Agi-
lent Technologies, Inc.), and the manufacturer’s software
to assign RINs [25]. The RINs that were measured for dif-
ferent lots of commercial human RNA are in Table 1.
Analyte Selection
UHRR, HBRR, liver RNA, and skeletal muscle RNA
were individually labeled using the 3’ IVT Express kit
(Method 1A) and hybridized to Human Genome U133A
2.0 arrays (Affymetrix, Santa Clara, CA). Three replicate
datasets were created by labeling and hybridizing the
four tissue RNA samples on separate dates to introduce
technical variation. The commercial lots of RNA used
for analyte selection are indicated in Table 1. For each
replicate dataset, the log2 signal intensities were derived
and quantile normalized using the Robust Multichip
Analysis (RMA) algorithm in the Affymetrix Expression
Console software. A mean TSI for each probe set was
calculated from the three replicate datasets and the
threshold for tissue selectivity was a mean TSI greater
than 3.22 log2 units. For the MTRC-4, 429 HBRR-, 255
liver RNA-, 197 UHRR-, and 154 skeletal muscle RNA-
selective analytes were identified (see Additional file 1 -
Lists of MTRC-4 analytes for Affymetrix HG-U133A 2.0
arrays). With omission of the UHRR from the compari-
son, 586 HBRR-, 384 liver RNA-, and 181 skeletal mus-
cle RNA-selective analytes were identified as analytes for
the MTRC-3 (see Additional file 2 - Lists of MTRC-3
analytes for Affymetrix HG-U133A 2.0 arrays).
Mixture Design
Four batches of MTRC-4 were prepared using total
RNA from four human tissues from different lots (Table
1). Batches 1-3 were tested in singlicate measurements
(Trials 1-3) and Batch 4 was used in all of the other
MTRC-4 datasets. A 100 μg batch of MTRC-4 Mix1
contains 20 μg UHRR, 30 μg liver RNA, 40 μgH B R R
RNA, and 10 μg skeletal muscle RNA. A 100 μgb a t c h
of MTRC-4 Mix2 contains 20 μgU H R R ,2 0μgl i v e r
RNA, 20 μgH B R RR N A ,a n d4 0μgs k e l e t a lm u s c l e
RNA. The ratio of total RNA contributed by UHRR,
liver, HBRR and skeletal muscle between Mix1 and
Mix2 in the MTRC-4 is 1:1, 1.5:1, 2:1, and 1:4, respec-
tively. UHRR was used for the 1-to-1 component in the
MTRC-4 to minimize the impact on the observed mixed
ratio due to the higher fraction of mRNA in the cell line
derived total RNA than in sources of tissue RNA like
the HBRR [11]. Human liver RNA, which was found to
have a higher RIN value across commercial lots than
the other components, was used for the ratio more sen-
sitive to performance differences (1.5-fold). Of the
remaining two components, the HBRR was selected for
measuring 2-fold changes because it contained the lar-
ger number of tissue-selective analytes.
MTRC-3 were prepared from total RNA from three
human tissues using the lots indicated for Batch 5 in
Table 1 and mixed to provide a 1:1 ratio for HBRR and
reciprocal 1.5:1 ratios for liver and muscle RNAs. A 100
μg batch of MTRC-3 Mix1 contained 25 μgH B R R
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Page 8 of 11RNA, 45 μg liver RNA, and 30 μg skeletal muscle RNA.
A 100 μg batch of MTRC-3 Mix2 contained 25 μg
HBRR RNA, 30 μg liver RNA, and 45 μg skeletal muscle
RNA. With the HBRR as the 1-to-1 component in the
MTRC-3, a similar number of true negatives (586 brain
RNA-selective analytes) and true positives (565 com-
bined liver RNA- and skeletal muscle RNA-selective
analytes) could be used in the ROC-plot analyses.
Target preparation
Labeled target was prepared from total RNA samples
using one of the following three reagent kits: (1) 3’ IVT
Express kit (Affymetrix Part No. 901229), (2) IVT kit
(Affymetrix Part No. 900449), or (3) Ovation RNA
Amplification System V2 and the FL-Ovation cDNA Bio-
tin module kits (Nugen Catalog Nos. 3100 and 4200).
Labeled target was hybridized to Affymetrix Human Gen-
ome U133A 2.0 arrays in a GeneChip Hybridization
Oven 640. The arrays were washed on an Affymetrix
GeneChip Fluidics Station 450 using fluidics protocol
FS450-002 and scanned using an Affymetrix GeneChip
Scanner 3000 7G. The variations made in protocols for
each target labeling method are listed in Table 3. For
each method, a pair of MTRC was run in triplicate but
processed on different days to create sets of technical
replicates. The microarray data from this study are avail-
able in the ArrayExpress Archive at the European Bioin-
formatics Institute through accession number E-TABM-
1091 http://www.ebi.ac.uk/arrayexpress.
Normalization
Each dataset that was created using a different target
labeling protocol or different batch of MTRC was pro-
cessed separately with RMA. The selective analytes for
the 1-to-1 component (UHRR for the MTRC-4 and
HBRR for the MTRC-3) were used to normalize Mix2
with respect to Mix1. For each technical replicate, the
difference in the 10% trimmed mean intensity between
the Mix1 and Mix2 data for analytes in the 1-to-1 com-
ponent was calculated and used to correct the Mix2 sig-
nal data.
ROC-plots
For ROC-plot calculations using the MTRC, the true
negatives are the tissue selective analytes for tissue RNA
that is mixed in a 1-to-1 ratio between Mix1 and Mix2.
Separate ROC-plots are generated for each true positive
subset in the MTRC. For MTRC-4, the true positives are
the 1.5-, 2-, and 4-fold changes and for the MTRC-3, the
true positives are the 1.5-fold changes in both directions.
For singlicate assays, analytes are ranked by log2 ratio
[14]. For replicate assays, analytes are ranked by p-values
calculated using a paired t-test comparison of the three
Mix1 and Mix2 signals. AUCs were calculated using the
trapezoidal method. Statistical analyses of differences in
AUCs were performed as previously described [14] using
the method of Hanley and McNeil [26].
RI-plots
For each dataset, the normalized log2 signals were aver-
aged across technical replicates of either Mix1 or Mix2.
The average log2 signals (¯ S)f o rM i x 1a n dM i x 2w e r e
then used to calculate the ratio (R) and intensity (I) for
each analyte as follows:
R = ¯ SMix1 − ¯ SMix2 (2)
I = 1
2
¯ SMix1 + ¯ SMix2

(3)
LRD-plots
For MTRC-4 datasets, the analytes (excluding the 1-to-1
component) were distributed into 19 bins of 42, with a
s i n g l eb i no f4 0a tt h el o w e s ti n t e n s i t y .F o rM T R C - 3
datasets, the analytes (excluding the 1-to-1 component)
were distributed into 20 bins of 28 analytes, omitting
the 5 lowest intensity analytes. The standard deviation
(s) ranged from 0.30 - 0.34 for MTRC-4 datasets and
from 0.16 - 0.21 for MTRC-3 datasets.
Additional material
Additional file 1: Lists of MTRC-4 analytes for Affymetrix HG-U133A
2.0 arrays. Analytes selective for HBRR, human liver RNA, human skeletal
muscle RNA, and UHRR are identified by Affymetrix probe set identifier,
gene name (annotation date 3-17-2008), and Tissue Selective Index (TSI).
This file is formatted as an Excel spreadsheet.
Additional file 2: Lists of MTRC-3 analytes for Affymetrix HG-U133A
2.0 arrays. Analytes selective for HBRR, human liver RNA, and human
skeletal muscle RNA are identified by Affymetrix probe set identifier,
gene name (annotation date 3-17-2008), and Tissue Selective Index (TSI).
This file is formatted as an Excel spreadsheet.
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